Post-Novartis, GSK Assures Immuno-Oncology R&D Running At Full Speed

Working with partners, GSK aims to have at least two new cancer immunotherapies in the clinic by mid-2015, says Axel Hoos, the former BMS exec who developed the checkpoint grandfather Yervoy.

The immuno-oncology effort at GlaxoSmithKline PLC “continues at full speed” following the recent sale of marketed cancer drugs to Novartis AG, according to GSK’s Oncology R&D VP Axel Hoos.

R&D was excluded from the sale of the British pharma’s marketed oncology drugs to Novartis in April for $14.5 billion...

More from Clinical Trials

More from R&D